How have IPATF shares performed in 2024?

ImmunoPrecise Antibodies' stock was trading at $1.71 on January 1st, 2024. Since then, IPATF shares have decreased by 26.9% and is now trading at $1.25. View the best growth stocks for 2024 here .

How do I buy shares of ImmunoPrecise Antibodies?

Shares of IPATF stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here .

OTCMKTS:IPATF

ImmunoPrecise Antibodies (IPATF) Stock Price, News & Analysis

→ 😱 This phenomenon is smashing regular market gains (From MillPub) (Ad)

Free IPATF Stock Alerts

$1.25

-0.03 (-2.34%)

(As of 05/1/2024 ET)

Compare

Today's Range: $1.23
▼
$1.29
50-Day Range: $1.19
▼
$1.90
52-Week Range: $1.15
▼
$20.25

Volume: 39,353 shs
Average Volume: 20,327 shs
Market Capitalization: N/A

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: N/A

Stock Analysis Chart

Get ImmunoPrecise Antibodies alerts:

Ad Crypto Swap Profits

He Is Giving Away Bitcoin

And my special guest is willing to give you $10 in Bitcoin (BTC) if you take it seriously. Right now is a very important time to pay attention to what we are doing and what is happening. If you wait... it will be too late. This week we are holding several workshops and if you attend and pay attention my special guest is going to send you $10 in Bitcoin.

>> Register right here

About ImmunoPrecise Antibodies Stock (OTCMKTS:IPATF)

ImmunoPrecise Antibodies Ltd. engages in the provision of human therapeutic antibody discovery and development services. It offers a selection of antibodies, enzymes, enzymes activity assays, arthritis animal products, proteins, deiminated proteins, and hybridoma licensing for research purposes. Its services include B cell sorting, screening and sequencing; custom, immune and naive phage display production and screening; bi-specific, tri-specific, VHH, and VNAR antibody manufacturing; antibody engineering; and antibody optimization and humanization. The company was founded by Robert Beecroft on November 22, 1983 and is headquartered in Victoria, Canada.

IPATF Stock Price History

30 days | 90 days | 365 days | Advanced Chart

IPATF Stock News Headlines

March 28, 2024 | benzinga.com

EXCLUSIVE: Immunoprecise Antibodies and InterSystems Integrate Vector Search With LENSai For AI-Driven Healthcare Applications

February 12, 2024 | benzinga.com

ImmunoPrecise Antibodies (NASDAQ: IPA) Is Changing How We Look At The Complex World Of Antibody Discovery

May 2, 2024 | Porter & Company (Ad)

Trump’s last act as President

You’ve probably never heard of Executive Order #13972. Signed by President Trump just days before leaving office, it greenlit what could be the most revolutionary technology of the decade… yet it has nothing to do with AI, blockchain, or mRNA vaccines.

March 17, 2023 | stockhouse.com

ImmunoPrecise Antibodies' Subsidiary Talem Therapeutics Announces a Multi-Target AI-Driven Antibody Discovery Collaboration with Libera Bio

September 15, 2022 | seekingalpha.com

ImmunoPrecise Antibodies reports FQ1 results

See More Headlines

Receive IPATF Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for ImmunoPrecise Antibodies and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Stock Exchange: OTCMKTS
Sector: Medical
Industry: Biotechnology
Sub-Industry: N/A
Current Symbol: OTCMKTS:IPATF
CUSIP: N/A
CIK: N/A
Web: www.immunoprecise.com
Phone: (250) 483-0308
Fax: N/A
Employees: N/A
Year Founded: N/A

Profitability

EPS (Most Recent Fiscal Year): N/A
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: N/A
Net Margins: N/A
Pretax Margin: N/A
Return on Equity: N/A
Return on Assets: N/A

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: N/A
Quick Ratio: N/A

Sales & Book Value

Annual Sales: N/A
Price / Sales: N/A
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: N/A
Price / Book: N/A

Miscellaneous

Outstanding Shares: N/A
Free Float: N/A
Market Cap: N/A
Optionable: Not Optionable
Beta: N/A

13 Stocks Institutional Investors Won't Stop Buying

Which stocks are major institutional investors including hedge funds and endowments buying in today's market? Click the link below and we'll send you MarketBeat's list of thirteen stocks that institutional investors are buying up as quickly as they can.

Get This Free Report

Key Executives

Jennifer Bath
President, Chief Executive Officer & Director
Lisa Helbling
Chief Financial Officer
Yasmina Noubia Abdiche
Chief Scientific Officer
Stefan Lang
Chief Business Officer
Kari Graber
VP-Client Relations & Project Management

Key Competitors

View All Competitors

IPATF Stock Analysis - Frequently Asked Questions

How have IPATF shares performed in 2024?: ImmunoPrecise Antibodies' stock was trading at $1.71 on January 1st, 2024. Since then, IPATF shares have decreased by 26.9% and is now trading at $1.25.
View the best growth stocks for 2024 here.
How do I buy shares of ImmunoPrecise Antibodies?: Shares of IPATF stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (OTCMKTS:IPATF) was last updated on 5/2/2024 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial